GlassScriptPhysician profile
Monzer Yazji
NPI 1619998838
$72,047.81
in general payments reported to CMS, 2019-2025
23 companies · $20.44 in 2025
The $20.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $7,313 · 2021: $15K · 2022: $11K · 2023: $5,633 · 2024: $2,230 · 2025: $20.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,564 · Debt Forgiveness: $270 · Food and Beverage: $49.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,563.75 |
| Debt Forgiveness | $270.00 |
| Food and Beverage | $49.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $71,096.94 | 2019-2024 | Rybelsus, Ozempic |
| Baxter Healthcare | $270.00 | 2024 | |
| Lilly USA, LLC | $109.52 | 2019-2022 | |
| Galderma Laboratories, L.P. | $91.07 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $85.89 | 2022 | |
| Allergan, INC. | $64.24 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $61.46 | 2019-2021 | |
| Abbott Laboratories | $45.34 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $37.91 | 2019 | |
| Mannkind Corporation | $34.21 | 2019-2020 | |
| Amgen INC. | $23.76 | 2019 | |
| Medtronic Minimed, INC. | $23.46 | 2019 | |
| Phadia US INC. | $20.44 | 2025 | Immunocap |
| Redhill Biopharma INC. | $16.33 | 2020 | |
| Genentech USA, INC. | $15.03 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.21 | 2022 | |
| Glaxosmithkline, LLC. | $13.65 | 2023 | Shingrix, Arexvy |
| Cumberland Pharmaceuticals, INC. | $12.19 | 2019 | |
| Tactile Systems Technology INC | $12.16 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monzer Yazji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.